TSX closed
Loading markets…

Advertisement

Stocks

Why Avricore Health Inc stock surged yesterday

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:AVCR.V

Follow AVCR

Photos provided by Pexels

Avricore Health Inc experienced a remarkable surge in its stock price, gaining 50% in a single trading session.

Avricore Health Inc (AVCR.V) saw its stock price climb significantly yesterday, closing at CA$0.09 after an impressive 50% increase. This surge can be attributed to positive developments surrounding the company's innovative HealthTab™ platform and strategic partnerships.

Advertisement

Avricore Health Inc

AVCR.V

Full stock page →

AVCR.V

Avricore Health Inc

Source:WealthAwesomeWealthAwesome
↓ $0.03 (-31.25%)
120 day period
$0.05$0.07$0.09Jan 28May 28Oct 1

Market cap

$6.95M

52W high

$0.10

52W low

$0.04

1W change

-15.38%

Beta

0.36

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on AVCR's historical volatility

HistoricalForecast68%95%
C$0.00C$0.14C$0.27C$0.40C$0.53C$0.66TodayApr 2Jun 23Oct 1Nov 13Dec 27Feb 8

30-Day Vol

205.9%

Annualized

90-Day Vol

155.1%

Annualized

Trend (90d)

+0.0%

Annualized drift

90d Mean

C$0.06

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.06C$0.03 – C$0.11
60 trading daysC$0.06C$0.02 – C$0.15
90 trading daysC$0.06C$0.02 – C$0.19

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should consider Avricore's recent performance as a signal of growing market confidence in its business model and future prospects.

50% Surge in Stock Price

Avricore Health Inc's stock price increased from CA$0.06 to CA$0.09 in yesterday's trading session, reflecting strong investor interest.

Bull case

The recent collaboration with Abbott to distribute point-of-care testing products through HealthTab™ positions Avricore as a leader in pharmacy-based healthcare solutions. This partnership could lead to significant revenue growth as more pharmacies adopt their innovative testing methods.

Bear case

Despite yesterday's gains, investors should remain cautious. Avricore's stock still faces volatility, and its long-term success depends on how well it executes its growth strategies and gains acceptance in the market.

Advertisement

Key Developments Fueling Growth

Avricore's recent announcement about granting stock options and its collaboration with Abbott has generated excitement among investors. The partnership aims to enhance the HealthTab™ platform, designed to improve patient care through rapid testing in community pharmacies. This innovative approach is expected to significantly expand Avricore's market presence.

Market Response and Future Outlook

The market's positive response to Avricore's developments indicates strong investor confidence. However, potential investors should keep an eye on the company's ability to effectively execute its growth strategies. As Avricore continues to innovate and expand, its stock performance will closely tie to its operational success and market conditions.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 31, 2026
Last Updated: September 22, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement